Process map proposal for the validation of genomic biomarkers (Q36555934)

14 August 2017

1 reference

title

Process map proposal for the validation of genomic biomarkers (English)

1 reference

14 August 2017

0 references

Federico Goodsaid

1

1 reference

PubMed ID

16886901

14 August 2017

Felix Frueh

series ordinal

2

1 reference

14 August 2017

1 July 2006

1 reference

14 August 2017

1 reference

14 August 2017

7

1 reference

14 August 2017

5

1 reference

14 August 2017

773-782

1 reference

Large-scale gene expression analysis in molecular target discovery

14 August 2017

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.773

Preclinical drug safety analysis by chemogenomic profiling in the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.773

Development and use of biomarkers in oncology drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.773

Workgroup report: Review of genomics data based on experience with mock submissions--view of the CDER Pharmacology Toxicology Nonclinical Pharmacogenomics Subcommittee

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.773

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.773

Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.773

Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.773

Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.773

Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.773

A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.773

Pharmacogenetics of the proton pump inhibitors: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.773

Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.773

Clinical consequences of cytochrome P450 2C9 polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.773

Equal proportion of adult male and female homozygous for the 677C ? T mutation in the methylenetetrahydrofolate reductase polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.773

Fluoxetine metabolism and pharmacological interactions: the role of cytochrome p450

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.773

Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.773

Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.773

Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.773

Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.773

Polymorphisms in the CYP 2D6 gene: association with plasma concentrations of fluoxetine and paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.773

The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 and plasma [2-13C]dihydrouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.773

Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.773

Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.773

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.773

Erlotinib in lung cancer - molecular and clinical predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.773

Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.773

Rasburicase: an innovative new treatment for hyperuricemia associated with tumor lysis syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.773

Rapid epidemiologic assessment of glucose-6-phosphate dehydrogenase deficiency in malaria-endemic areas in Southeast Asia using a novel diagnostic kit.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.773

Expression and amplification of HER-2/neu oncogene in uterine carcinosarcomas: a marker for potential molecularly targeted treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.773

HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.773

Pharmacogenomics and individualized drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.773

The thiopurines: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.773

Thiopurine methyltransferase (TPMT) heterozygosity and enzyme activity as predictive tests for the development of azathioprine-related adverse events.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.773

The clinical impact of thiopurine methyltransferase polymorphisms on thiopurine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.773

Assessment of thiopurine methyltransferase and metabolite formation during thiopurine therapy: results from a large Swedish patient population

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.773

Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.773

Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.773

Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.773

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.773

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.773

A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.773

A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.773

Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.773

21 January 2018

Identifiers

DOI

10.2217/14622416.7.5.773

1 reference

14 August 2017

1 reference

PubMed ID

16886901